ANI Pharmaceuticals, Inc. delivered robust 2025 results and issued bullish 2026 guidance. Learn more about ANIP stock here.

Amid the dozens of publicly traded firms in Minnesota, Baudette-based ANI Pharmaceuticals Inc. often flies under the radar. The pharmaceutical company about five hours north of Minneapolis has grown ...

Indian news agency ANI has filed a lawsuit against OpenAI, alleging copyright infringement. ANI claims OpenAI used its content without permission to train its AI chatbot, ChatGPT, and even attributed ...

What Happened? Shares of specialty pharmaceutical company ANI Pharmaceuticals (NASDAQ:ANIP) fell 3.3% in the morning session ...

Piper Sandler has initiated coverage on ANI Pharmaceuticals (NASDAQ:ANIP), an integrated specialty pharmaceutical firm that develops and markets branded and generic medicines. The analyst notes that ...

ANI is growing its capabilities and pipeline with an acquisition. The company has signed a definitive agreement to acquire Novitium Pharma for $163.5 million, including $89.5 million in cash and $74 ...

-- Combined company creates generics growth engine with technical capabilities to bring complex, high-value products to market in efficient and cost effect manner -- -- Proven track record with ...

New Delhi: The storm over Asian News International’s (ANI) copyright strikes on YouTubers may have a far-reaching impact on the future of content creation, creator protection, and platform ...

-- ANI Pharmaceuticals appoints Mary Pao, M.D., Ph.D., as Chief Medical Officer, Rare Disease, and Elizabeth Powell, J.D., as Chief Compliance Officer and Head of ...

ANI Pharmaceuticals offers an asymmetric opportunity in small-cap pharma, with a niche in generics, rare disease treatments, and contract manufacturing. Despite cash burn concerns, ANI's revenue ...